Mesenchymal stromal cells: potential option for COVID-19 treatment (CROSBI ID 321168)
Prilog u časopisu | pregledni rad (znanstveni) | međunarodna recenzija
Podaci o odgovornosti
Primorac, Dragan ; Čemerin, Martin ; Matišić, Vid ; Molnar, Vilim ; Strbad, Marko ; Girandon, Lenart ; Zenić, Lucija ; Knežević, Miomir ; Minger, Stephen ; Polančec, Denis
engleski
Mesenchymal stromal cells: potential option for COVID-19 treatment
The COVID-19 pandemic has significantly impacted the way of life worldwide and continues to bring high mortality rates to at-risk groups. Patients who develop severe COVID-19 pneumonia, often complicated with ARDS, are left with limited treatment options with no targeted therapy currently available. One of the features of COVID- 19 is an overaggressive immune reaction that leads to multiorgan failure. Mesenchymal stromal cell (MSC) treatment has been in development for various clinical indications for over a decade, with a safe side effect profile and promising results in preclinical and clinical trials. Therefore, the use of MSCs in COVID-19-induced respiratory failure and ARDS was a logical step in order to find a potential treatment option for the most severe patients. In this review, the main characteristics of MSCs, their proposed mechanism of action in COVID-19 treatment and the effect of this therapy in published case reports and clinical trials are discussed.
COVID-19 ; mesenchymal stromal cells ; MSCs ; immunomodulation ; ARDS
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
Povezanost rada
Farmacija, Temeljne medicinske znanosti